ArticleiMeta2026
Dietary fiber-based oral nanovaccine promotes gut-to-nose trafficking of regulatory cells and drives antigen-specific tolerance to relieve airway allergy.
Article in iMeta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current therapies for allergic rhinitis primarily provide symptomatic relief but fail to establish durable antigen-specific immune tolerance. Here, we developed an oral nano-dietary fiber (NDF) platform that integrates allergen delivery with microbiota-driven immunomodulation, using dextran as both an antigen carrier and a fermentable substrate for intestinal bacteria. NDF enabled coordinated allergen release and sustained short-chain fatty acid (SCFA) production in the gut, promoting SCFA-FFAR2-dependent expansion of regulatory B and T cells and their trafficking to the nasal mucosa. In murine models, NDF slowed disease progression, improved airway function, and reduced allergen-specific IgE levels. Together, these findings establish NDF as an oral tolerogenic vaccine that provides durable protection against allergic airway disease through the gut-nasal axis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.